Rabbit Recombinant Monoclonal BRCA2 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SEM1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180).
FACD, FANCD1, BRCA2, Breast cancer type 2 susceptibility protein, Fanconi anemia group D1 protein
Rabbit Recombinant Monoclonal BRCA2 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Negative control: Capan-1 (PMID:16251802).
Lysates were freshly made and used for Western blotting immediately to minimize protein degradation.
Blocking and diluting buffer: 5% NFDM/TBST
All lanes: Western blot - Anti-BRCA2 antibody [EPR23442-43] (ab239375)
Lane 1: HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 100 µg
Lane 2: Capan-1 (human pancreas adenocarcinoma epithelial cell) whole cell lysate at 100 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/10000 dilution
Predicted band size: 384 kDa
Exposure time: 180s
Anti-BRCA2 antibody [EPR23442-43] (ab239375) staining at 1/500 dilution, shown in green; Mouse anti-CANX [CANX/1543] (Anti-Calnexin antibody [CANX/1543] ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab239375 was shown to bind specifically to BRCA2. A band was observed at 290 kDa in wild-type MCF7 cell lysates with no signal observed at this size in BRCA2 knockout cell line Human BRCA2 knockout (hetero) MCF7 cell line ab286285 (knockout cell lysate ab300210). To generate this image, wild-type and BRCA2 knockout MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween$®$ 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
All lanes: Western blot - Anti-BRCA2 antibody [EPR23442-43] (ab239375) at 1/500 dilution
Lane 1: Wild-type MCF7 cell lysate at 20 µg
Lane 2: Western blot - Human BRCA2 knockout MCF7 cell lysate (ab300210) at 20 µg
Lane 3: Jurkat cell lysate at 20 µg
Lane 4: PC-3 cell lysate at 20 µg
Lane 5: HT-29 cell lysate at 20 µg
Lanes 1 - 5: Goat anti-Rabbit IgG H&L 800CW at 1/20000 dilution
Lanes 1 - 5: Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Observed band size: 290 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com